United Therapeutics Co. (NASDAQ:UTHR) Holdings Lifted by Compass Ion Advisors LLC

Compass Ion Advisors LLC lifted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 3.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,892 shares of the biotechnology company’s stock after buying an additional 101 shares during the period. Compass Ion Advisors LLC’s holdings in United Therapeutics were worth $664,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Rise Advisors LLC bought a new position in shares of United Therapeutics in the first quarter worth $32,000. GAMMA Investing LLC bought a new position in United Therapeutics in the 4th quarter valued at about $43,000. Janiczek Wealth Management LLC increased its stake in United Therapeutics by 21.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 84 shares during the period. Blue Trust Inc. raised its position in shares of United Therapeutics by 10.0% during the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock worth $114,000 after buying an additional 46 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its stake in shares of United Therapeutics by 31.2% in the 4th quarter. Quadrant Capital Group LLC now owns 581 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 138 shares during the period. 94.08% of the stock is owned by institutional investors.

Insider Activity

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $316.62, for a total transaction of $1,139,832.00. Following the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $41,160.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $316.62, for a total transaction of $1,139,832.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $41,160.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $232.37, for a total transaction of $1,394,220.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at $8,530,302.70. The disclosure for this sale can be found here. Insiders sold 126,344 shares of company stock worth $32,426,462 over the last quarter. Corporate insiders own 12.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on UTHR. The Goldman Sachs Group raised their price objective on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Oppenheimer boosted their price objective on United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 20th. JPMorgan Chase & Co. boosted their price target on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $300.00 price target on shares of United Therapeutics in a report on Thursday, May 2nd. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $312.22.

United Therapeutics Price Performance

NASDAQ UTHR opened at $318.55 on Monday. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $321.80. The stock’s 50-day moving average price is $274.77 and its two-hundred day moving average price is $243.95. The company has a market cap of $14.13 billion, a PE ratio of 15.06, a PEG ratio of 1.40 and a beta of 0.55. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The business had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. During the same quarter in the previous year, the business earned $4.86 earnings per share. The firm’s revenue was up 33.7% compared to the same quarter last year. On average, analysts predict that United Therapeutics Co. will post 24.73 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.